Home › Sjogren's Syndrome › Missouri › Kansas City
Sjogren's Syndrome clinical trials in Kansas City, MO
3 studies for Sjogren's Syndrome are looking for participants at sites in and around Kansas City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi away
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
RecruitingPhase 3
- Kansas City Physician Partners, Kansas City
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
RecruitingPhase 3
- Kansas City Physician Partners-8350 N Saint Clair Ave, Kansas City
About Sjogren's Syndrome
Sjogren's Syndrome is an autoimmune disease that causes dryness of the mouth, eyes and other parts of the body. Learn how to relieve the symptoms.
More about Sjogren's Syndrome on MedlinePlus
Sjogren's Syndrome trials in other cities
- Houston, TX6 studies
- Boston, MA5 studies
- Washington, DC5 studies
- Arlington, TX4 studies
- Tampa, FL4 studies
- Charlotte, NC4 studies
- Cicero, IL4 studies
- Clearwater, FL3 studies
- Warren, MI3 studies
- Cypress, TX3 studies
- Tucson, AZ3 studies
- Orlando, FL3 studies
Other studies in Kansas City
- Breast Cancer34 studies
- Non-Small Cell Lung Cancer31 studies
- Heart Failure25 studies
- Cancer (all types)21 studies
- Lung Cancer19 studies
- Colorectal Cancer16 studies
- Metastatic Cancer15 studies
- Acute Myeloid Leukemia15 studies
- Prostate Cancer14 studies
- Ovarian Cancer11 studies
- Obesity11 studies
- Type 2 Diabetes11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.